Obecabtagene autoleucel (autologous)
Class
CAR T cell therapy
Subclass
CD19-directed genetically modified autologous T cells
Substance name
Obecabtagene autoleucel, obe-cel
Brand names
Aucatzyl®
Common formulations
Suspension
Indications for use
Labeled indications
Adults
Safety risks
Boxed warnings
Cytokine release syndrome
Immune effector cell-associated neurotoxicity syndrome
T-cell malignancies
Contraindications
Active infection or inflammatory disorders
Use of live vaccines
Warnings and precautions
Cytopenias
Hemophagocytic lymphohistiocytosis, macrophage activation syndrome
Hypersensitivity reactions
Hypogammaglobulinemia
Infections
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Use only if benefits outweigh potential risks.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource